PTC Therapeutics: Sephience Launch Generates Record Sales and 2 Billion USD Opportunity
Reading Time: 3 minutes
Business Model: PTC Therapeutics focuses on the targeted modulation of RNA biology to provide treatments for diseases such as Duchenne muscular dystrophy (DMD) and phenylketonuria (PKU). Sephience with Blockbuster Potential: The launch of Sephience results in record sales. The peak sales potential exceeds 2 billion USD. Positive Study Data: Long-term data from the drug Votoplam for Huntington's disease leads to a milestone payment of 50 million USD from Novartis. Biotech stocks are forming a strong industry trend, with PTC Therapeutics...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
